


Activating receptors



Supplementary Figure S3. Pretreatment NKs and Tregs in mRCC-REV patients. (A) Upper: frequency of $\text{NKp44}^+\text{NKs}$, $\text{NKp46}^+\text{NKs}$ and $\text{NKp30}^+\text{NKs}$ in HD and REV patients. $\text{NKp44}^+\text{NKs}$: HD (n=18) vs REV (n=38), $p < 0.001$; $\text{NKp46}^+\text{NKs}$: HD (n=18) vs REV (n=31), $p < 0.001$, $\text{NKp30}^+\text{NKs}$: HD (n=18) vs REV (n=36), $p < 0.01$. Lower: representative comparison between HD#2 and REV#72; HD#104 and REV#42; HD#3 and REV#34 with negative controls; (B) Upper: frequency of $\text{KIR2DL1}^+\text{NKs}$ and $\text{KIR2DL2/DL3}^+\text{NKs}$ in HD and REV patients. $\text{KIR2DL1}^+\text{NKs}$: HD (n=37) vs REV (n=50), $p < 0.001$; $\text{KIR2DL2/DL3}^+\text{NKs}$: HD (n=39) vs REV (n=51), $p < 0.05$. Lower: representative comparison between HD#1449 and REV#68; HD#11 and REV#35 with negative controls; (C) Upper: frequency of $\text{Helios}^+\text{Tregs}$ and $\text{ENTPD1}^+\text{Tregs}$ in HD and REV patients. $\text{Helios}^+\text{Tregs}$: HD (n=11) vs REV (n=43), $p < 0.05$, $\text{ENTPD1}^+\text{Tregs}$: HD (n=31) vs REV (n=55), $p < 0.01$. Lower: representative comparison between HD#5 and REV#67; HD#9 and REV#26 with negative controls; (D) Upper: $\text{PD-1}^+\text{CD8}$ and $\text{PD-1}^+\text{CD4}$ cells in HD and REV groups. $\text{PD-1}^+\text{CD8}$: HD (n=32) vs REV (n=52), $p < 0.01$, $\text{PD-1}^+\text{CD4}$: HD (n=32) vs REV (n=53), $p < 0.05$. Lower: representative comparison between HD1299 and REV#35; HD#1456 and REV#23 with negative controls. Box plot showing the data distribution across groups with minimum, median, and maximum value. Two tailed test comparison of differences between two independent groups (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$).